AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01132703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide for Injection
Description: Administered as specified in the Treatment Arm.
Study NCT01132703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the Treatment Arm.
Study NCT03500289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes
Study NCT03500289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes
Study NCT02791347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention
Study NCT03167138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous micro-fragmented adipose tissue
Description: Micro-fragmented adipose tissue is obtained from abdominal region or thighs using the Lipogems® system and injected into the injury site under ultrasound guidance.
Study NCT03167138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems system
Description: The Lipogems® system is a non-enzymatic method to obtain micro-fragmented adipose tissue from the abdominal region or thighs for injection into the injury site.
Study NCT02035904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patrol
Description: tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
Study NCT00521027 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional surgical debridement techniques
Description: Conventional surgical debridement with scalpel and pulse lavage
Study NCT02944383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene tablets administered orally once daily, for 12 weeks.
Study NCT02944383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets administered orally once daily, for 12 weeks.
Study NCT02245321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous gluconate- 19 mg
Description: Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
Study NCT02245321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous gluconate- 38 mg
Description: Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
Study NCT02245321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letter Group- Information Provided
Description: Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
Study NCT02245321 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Letter - No Information Provided
Description: Receive a letter thanking the participant for their participation.
Study NCT03122067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin treatment
Description: intranasal administration of oxytocin
Study NCT03122067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: intranasal administration of placebo
Study NCT02245321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receive pills to take daily that contain 0 mg iron.
Study NCT01435174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: A single dose of two oral ranolazine extended release 500 mg tablets
Study NCT01435174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Blood and Dialysate Sampling
Description: Blood samples collected to assess ranolazine plasma and dialysate concentrations.
Study NCT01435174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QT Interval
Description: Calculation of a QT interval will be performed throughout subject participation.
Study NCT00083980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine ER
Description: 75 to 225 mg daily
Study NCT00083980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugar pill
Description: Upto 3 per day for venlafainxe and 4 per day for kava placebos.
Study NCT00083980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Upto 3 per day for venlafainxe and 4 per day for kava placebos.
Study NCT00083980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill
Description: Upto 3 per day for venlafainxe and 4 per day for kava placebos.
Study NCT02982031 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: shamrock
Description: This scanning technique is performed in the lateral decubitus position with the side of interest facing upwards. The transducer is placed in the transverse plane on the flank of the patient cranially to the iliac crest. The quadratus lumborum muscle is identified medial to the aponeurosis of the transversus abdominis muscle. With the psoas muscle anterior to the transverse process, the erector spinae muscle posterior to the transverse process, and the quadratus lumborum muscle attached to the apex of the transverse process of L4.
Study NCT02982031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paramedian transverse scan
Description: The ultrasound transducer is positioned 4 cm lateral to the midline along the intercristal line and just above the iliac crest. The transducer is also directed slightly medially.
Study NCT01449279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.
Study NCT01449279 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.
Study NCT02208674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized, pharmacist-delivered CKD Action Plan
Description: The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
Study NCT02500641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 80/120mg/day
Description: Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration > 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
Study NCT02500641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 100 up to 600mg/day
Description: Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
Study NCT02500641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
Study NCT02500641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
Study NCT02500641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
Study NCT02500641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
Study NCT02500641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
Study NCT02500641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
Study NCT02017548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-extension default advance directive
Study NCT02035904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patrol
Description: tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
Study NCT02017548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comfort default advance directive
Study NCT01058720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2000 IU orally once daily for 12 weeks
Study NCT01072474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capnography
Description: Capnographic monitoring
Study NCT01072474 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard monitoring
Description: Standard monitoring
Study NCT01536158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral paracetamol
Description: Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
Study NCT01536158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ibuprofen
Description: Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
Study NCT00083980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kava
Description: 140 to 280 mg per day
Study NCT02987101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Adipose tissue is harvested by liposuction from either abdomen or thighs.
Study NCT02987101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard wound care
Description: Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.
Study NCT02987101 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard wound care
Description: Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.
Study NCT02987101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-Derived Regenerative Cells
Description: Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
Study NCT00804713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BST
Description: 0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.
Study NCT00804713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST
Description: Administer TB Skin test (TST)
Study NCT00988858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2603618
Description: 150 milligram per square meter (mg/m\^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
Study NCT00988858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
Study NCT03927820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Benefits investigation
Description: The study pharmacist will review the prescribed inhaler for 1) insurance coverage and 2) clinical appropriateness. The pharmacist will conduct a benefits investigation at time of hospital admission. The benefits investigation involves running test claims for inhalers to determine the most cost-effective inhaler for the patient's insurance plan. The study pharmacist will utilize clinical practice guidelines to assess appropriateness of the prescribed inhaler. Based on this review, the study pharmacist will submit a pharmacy consult to the inpatient pharmacist on the patient's healthcare team who will pend the inhaler orders (changing the patient's prescribed inhaler, if necessary) for the prescriber to send to the Meds to Beds discharge pharmacy. The Meds to Beds pharmacist will counsel the patient on inhaler use techniques prior to discharge.
Study NCT00804713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QFT
Description: Perform QFT TB test
Study NCT00804713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-spot
Description: Perform T-Spot TB test
Study NCT01725321 — intervention group
Intervention type: OTHER
Intervention: Narrow band imaging
Description: Colonoscopy with new narrow band imaging
Study NCT02527928 — intervention group
Intervention type: OTHER
Intervention: None intervention
Study NCT02915965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCX
Description: docetaxel, cisplatin and capecitabine
Study NCT02915965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Ivor Lewis Esophagectomy
Study NCT03267875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test
Description: draw out 2 blood tubes from a patient
Study NCT03203486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Participants were instructed to include vegetables, whole grains and fruits in their diet and increase fish, legumes and raw nut intake. Emphasis was given to extra virgin olive oil as the main added fat in meals. Particular attention was drained to decrease fermented dairy and poultry, with small amounts of red meat and homemade sweets. All participants were given meal plans in which the distribution of nutrients in relation to total caloric value was as follows: 40% of total energy as fat (50% as MUFAs), 20% as protein, 40% as carbohydrate, 300mg/d as dietary cholesterol and 20-30g fiber/d.
Study NCT00380692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Study NCT00380692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01666197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium 25 mg tablet
Description: diclofenac potassium 25 mg tablet
Study NCT01666197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01416740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect MRA of shoulder
Description: Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
Study NCT01416740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate Dimeglumine
Description: Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
Study NCT04619290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Methylene blue
Description: Patients will be received the treatment as follow: it will be placed Low Level Light Therapy (LLLT) NocUlite on the ventral side of the wrist on full power. Draw out 1ml of diluted Prexablu into a syringe. Activate this syringe LLLT device for 10 minutes. Then place 1ml of this activated solution of Prexablu sublingually. Patients must keep the solution under the tongue for 10 minutes before swallowing. Keep wrist pads on patients for 50 minutes.
Study NCT00923000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: Nalbuphine 10mg with oral administration
Study NCT00923000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine 10mg with oral administration
Study NCT00923000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine with Long dan xie gan tang
Description: Morphine 10mg with oral administration
Study NCT00923000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine with Long dan xie gan tang
Description: Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
Study NCT00923000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nubian with Long dan xie gan tang
Description: Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
Study NCT01781000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Fitness & Brain Training- Posit Science
Description: Computer aided cognitive program designed for intensive training of auditory perception, memory and attention
Study NCT01781000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Affect Training- FAT
Description: Computer-aided cognitive program designed for intensive training of facial affect discrimination, memory and attention
Study NCT01781000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: standard treatment protocol of schizophrenia ward
Study NCT01432379 — intervention group
Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: 155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
Study NCT02075827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competitive video game
Description: 1 hour playing video game
Study NCT02075827 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Little Big Planet
Description: 1 hour playing video game
Study NCT00612430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Etoposide
Description: 32 pts w recurrent WHO grade III MG \& 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data \& order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
Study NCT04099173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness Based Intervention
Description: This intervention will consist of four, 45 minute individual mindfulness training sessions (one session per day, over a range of 12 subsequent days) provided by a trained mindfulness facilitator.
Study NCT04677881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: intervention group: bread with sourdough control group: bread with yeast
Study NCT04677881 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intervention group
Description: intervention group: bread with sourdough control group: bread with yeast
Study NCT00543608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iclaprim
Study NCT00543608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Study NCT00858962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg of raltegravir orally twice daily together with normally prescribed stable dose of buprenorphine for a minimum of 4 days and up to 14 days.
Study NCT03933436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodine swabs.
Description: Children will then have their periurethral region gently cleansed for ten seconds with iodine swabs.
Study NCT01323985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: 5mg-400mg IV (in the vein) single dose over 1-4 hours
Study NCT03933436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline flush.
Description: Children will then have their periurethral region gently cleansed for ten seconds with saline flush.
Study NCT05000086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99Tc methylene diphosphonate
Description: 22mg qd，Once a day for 7 consecutive days
Study NCT02932514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eversense (Senseonics) Continuous Glucose Monitoring System
Description: * Evaluate accuracy of Eversense CGM System to SMBG Meter.~* Compare performance between abdomen and arm insertion sites.~* Determine the usability of the Eversense System in a home-use setting for 180 days.